Glenmark begins human trials of GBR 830 to treat autoimmune diseases

Glenmark Pharmaceuticals' Swiss subsidiary has announced that its new monoclonal antibody GBR 830 is entering human trials for the treatment of autoimmune diseases.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news